Page last updated: 2024-11-05

ticlopidine and Coronary Restenosis

ticlopidine has been researched along with Coronary Restenosis in 272 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research Excerpts

ExcerptRelevanceReference
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."9.20Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."9.14Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency."9.14Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."9.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."9.12Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents."9.10A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."8.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation."7.85Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017)
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown."7.80Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."7.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."7.73[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."7.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."6.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders."5.206- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015)
"Clopidogrel is indicated for the treatment and prevention of peripheral vascular, cerebrovascular, and coronary artery diseases."5.20Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. ( Cho, DK; Kim, SH; Lee, HJ; Lee, HS; Lim, SW; Shin, J; Sung, JH, 2015)
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."5.20Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)."5.17Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013)
"A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident."5.16Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012)
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)."5.15Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011)
"This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting."5.14Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."5.14Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency."5.14Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010)
"The ISAR-REACT 2 trial was designed to assess the effect of abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after a 600-mg loading dose of clopidogrel."5.13Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. ( Dirschinger, J; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A; Seyfarth, M, 2008)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."5.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."5.12Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
"The findings of this study do not support a significant impact of abciximab on the risk of death and myocardial infarction in diabetic patients undergoing percutaneous coronary interventions after pretreatment with a 600-mg loading dose of clopidogrel at least 2 hours before the procedure."5.11Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. ( Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N, 2004)
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents."5.10A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."4.90Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
" In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis."4.88Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012)
"Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions."4.85Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009)
"The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria."4.85Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009)
" In addition to aspirin, whose benefit has been clearly demonstrated in all forms of ischemic heart disease, clopidogrel, given before and after cardiac catheterization, also reduces the rate of thrombosis after stent placement."4.82[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. ( Benito, B; Betriu, A; Masotti, M, 2005)
" In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel."4.81Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002)
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation."3.85Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017)
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol."3.81Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown."3.80Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014)
"The authors studied efficacy of the generic clopidogrel Еgithromb manufactured by EGIS PHARMACEUTICALS (Hungary) based on clinical data and parameters of light aggregometry in a total of 30 patients subjected to planned subcutaneous coronary intervention for stable angina pectoris."3.79[Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice]. ( Faĭl', IL; Loenko, VB; Smialovskiĭ, DV; Sorokina, EA, 2013)
" Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model."3.79The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013)
"Between September 2007 and April 2010, twelve patients receiving double antithrombotic therapy (clopidogrel+acetylsalicylic acid) underwent transurethral resection of bladder cancer."3.77Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. ( Arena, D; Bozzini, G; Carmignani, L; Casellato, S; Lunelli, L; Picozzi, S; Stubinski, R, 2011)
"Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia."3.75Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. ( Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ, 2009)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."3.73[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."3.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis."3.73Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. ( Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."3.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"Our study offers preliminary evidence that patients receiving a new PCI procedure for ISR may benefit from long-term administration of aspirin plus clopidogrel."2.79Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). ( Biscaglia, S; Campo, G; Ferrari, R; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2014)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."2.79Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding."2.75Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."2.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"0001), and major adverse cardiac events (8."2.73Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007)
"Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis."2.71Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003)
"Trapidil has been shown to prevent restenosis after PTCA."2.71Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. ( Balducelli, M; Barlera, S; Bernardi, G; Latini, R; Maggioni, AP; Maresta, A; Moccetti, T; Monici Preti, A; Ribeiro da Silva, EE; Sosa, C; Varani, E, 2005)
"Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use."2.70Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002)
"After balloon angioplasty of a subtotal or total coronary occlusion, no reduction in adverse events was observed among patients in whom ticlopidine was added to aspirin, even after adjustment for clinical and lesion characteristics."2.70Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001)
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation."2.49Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013)
" There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0."2.48The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012)
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."2.46[Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010)
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up."1.48The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018)
"Coronary pseudoaneurysm after bare-metal stent implantation is a rare event."1.39A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon. ( Palmieri, C; Vaghetti, M, 2013)
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."1.37Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)
"002) and major adverse cardiac events (OR: 0."1.36Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Only amlodipine was associated with clopidogrel poor-response."1.36The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010)
"Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent."1.35Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."1.34Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
"Aspirin was given starting 3 days before the intervention and administered for an additional 4 weeks."1.33Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. ( Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M, 2006)
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations."1.33Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006)
"Ticlopidine (200 mg/day) was prescribed for at least 12 weeks after SES implantation and for 2 weeks after BMS in addition to aspirin (81-100 mg/day)."1.33Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. ( Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Ohta, M; Okada, H; Sakamoto, H; Tsurusaki, T, 2006)
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."1.32Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)

Research

Studies (272)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's173 (63.60)29.6817
2010's98 (36.03)24.3611
2020's1 (0.37)2.80

Authors

AuthorsStudies
Osama, S1
Wirth, F1
Zahra, G1
Barbara, C1
Xuereb, RG1
Camilleri, L1
Azzopardi, LM1
Capodanno, D2
Kim, HK2
Jeong, MH5
Lim, KS2
Kim, JH6
Lim, HC1
Kim, MC1
Hong, YJ3
Kim, SS1
Park, KH3
Chang, KS1
Piccolo, R2
Feres, F5
Abizaid, A7
Gilard, M3
Morice, MC3
Hong, MK9
Kim, HS6
Colombo, A8
Bhatt, DL5
Palmerini, T1
Stone, GW3
Windecker, S3
Valgimigli, M8
Xue, Y1
Feng, ZW1
Li, XY1
Hu, ZH1
Xu, Q1
Wang, Z2
Cheng, JH1
Shi, HT1
Wang, QB1
Wu, HY1
Xie, XQ1
Lv, QZ1
Núñez-Gil, IJ1
Aldazábal, A1
Cerrato, E1
Salinas, P1
Pérez-Vizcayno, MJ3
Fernández-Ortiz, A1
Zhao, X2
Wu, H1
Xu, H1
Shen, L1
Fan, B1
Ge, J1
Kan, J1
Chen, F1
Liu, LY1
Xu, HM1
Lin, L1
Liu, Y3
Zhao, YY1
Cheng, JP1
Chen, SL1
Loenko, VB1
Sorokina, EA1
Faĭl', IL1
Smialovskiĭ, DV1
Vaghetti, M1
Palmieri, C1
Phankingthongkum, R1
Panchavinnin, P1
Chinthammitr, Y1
Tresukosol, D1
Chotinaiwattarakul, C1
Tungsubutra, W1
Wongpraparut, N1
Kitrattana, B1
Leewanun, P1
Lee, SW10
Lee, JY3
Ahn, JM1
Park, DW6
Han, S1
Park, YK1
Lee, WS1
Jang, JY1
Kwon, CH1
Park, GM1
Cho, YR1
Kim, WJ3
Kang, SJ3
Kim, YH8
Lee, CW9
Kim, JJ5
Park, SW9
Park, SJ9
Musumeci, G1
Limbruno, U2
Campo, G5
Tebaldi, M6
Vranckx, P5
Biscaglia, S1
Tumscitz, C4
Ferrari, R4
Borghesi, M4
Cangiano, E3
Minarelli, M3
Scalone, A3
Cavazza, C3
Marchesini, J3
Parrinello, G4
Youn, YJ1
Lee, JW1
Ahn, SG1
Lee, SH2
Choi, H1
Yu, CW1
Kwon, HM2
Jang, Y3
Yoon, J2
Tang, XF1
Fan, JY1
Meng, J1
Jin, C1
Yuan, JQ1
Yang, YJ1
Camenzind, E1
Boersma, E1
Wijns, W5
Mauri, L2
Rademaker-Havinga, T1
Ordoubadi, FF1
Suttorp, MJ1
Al Kurdi, M1
Steg, PG2
López Mínguez, JR1
Nogales Asensio, JM1
Doncel Vecino, LJ1
Sandoval, J1
Romany, S1
Martínez Romero, P1
Fernández Díaz, JA1
Fernández Portales, J1
González Fernández, R1
Martínez Cáceres, G1
Merchán Herrera, A1
Alfonso Manterola, F1
Une, D1
Al-Atassi, T1
Kulik, A1
Voisine, P1
Le May, M1
Ruel, M1
Barragan, P2
Noryani, AAL1
Noor, HA1
Majwal, T1
Hovasse, T1
Castellant, P1
Schneeberger, M1
Maillard, L1
Bressolette, E1
Wojcik, J1
Delarche, N1
Blanchard, D2
Jouve, B1
Ormezzano, O1
Paganelli, F2
Levy, G1
Sainsous, J1
Carrie, D2
Furber, A1
Berland, J2
Darremont, O1
Le Breton, H1
Lyuycx-Bore, A1
Gommeaux, A1
Cassat, C1
Kermarrec, A1
Cazaux, P1
Druelles, P1
Dauphin, R1
Armengaud, J1
Dupouy, P2
Champagnac, D1
Ohlmann, P1
Endresen, K1
Benamer, H2
Kiss, RG1
Ungi, I2
Boschat, J1
Kim, SH2
Sung, JH1
Shin, J1
Lee, HJ1
Lee, HS1
Cho, DK1
Lim, SW1
Yeh, RW1
Kereiakes, DJ2
Patialiakas, A1
Thury, A1
McFadden, E1
Colangelo, S1
Tondi, S1
Roffi, M2
Menozzi, A1
de Cesare, N1
Garbo, R1
Meliga, E1
Testa, L1
Gabriel, HM1
Airoldi, F3
Ferlini, M1
Liistro, F2
Dellavalle, A1
Briguori, C1
Kandzari, DE1
Hernandez-Perez, FJ1
Garcia-Touchard, A1
Restrepo-Cordoba, MA1
Rodriguez-Gonzalez, E1
Escudier-Villa, JM1
Cobo-Marcos, M1
Alonso-Pulpon, L1
Goicolea-Ruigomez, J1
Lee, SA1
Suh, JW1
Park, JJ1
Yoon, CH1
Cho, YS1
Youn, TJ1
Chae, IH3
Choi, DJ1
Liu, C1
Liu, M2
Chen, D1
Liu, H3
Jiang, Q1
Lu, J1
Zuo, L1
Azzalini, L1
Al-Hawwas, M1
L'Allier, PL1
Nozari, Y1
Vosooghi, S1
Boroumand, M1
Poorhosseini, H1
Nematipour, E1
Salarifar, M1
Kassaian, SE1
Amirzadegan, A1
Alidoosti, M1
Haji-Zeinali, AM1
Saroukhani, S1
Wei, YQ1
Wang, DG1
Yang, H1
Cao, H1
Capranzano, P2
Castiglioni, B1
Li, P1
Yang, Y2
Chen, T2
Cao, A1
Liu, J1
Qin, Y1
Ma, L1
Kagawa, Y1
Shiode, N1
Kawase, T1
Tamekiyo, H1
Okimoto, T1
Hayashi, Y2
Shah, RR1
Pillai, A1
Omar, A1
Zhao, J1
Arora, V1
Kapoor, D1
Poommipanit, P1
Sharma, GK1
Megaly, M1
Ma, W1
Liang, Y1
Zhu, J1
Feng, G1
Liu, X2
Wang, X1
Gargiulo, G1
Ariotti, S1
Santucci, A1
Baldo, A1
Franzone, A1
Magnani, G1
Marino, M1
Esposito, G1
Cho, MH1
Shin, DW1
Yun, JM1
Shin, JH1
Lee, SP1
Lee, H1
Lim, YK1
Kim, EH1
Zuliani Mauro, MF1
Mangione, JA1
Costa, JR4
Costa, R4
Piva E Mattos, LA1
Staico, R4
Siqueira, D3
Sousa, A2
Goodman, SG1
Nicolau, JC1
Requena, G1
Maguire, A1
Blankenberg, S1
Chen, JY1
Granger, CB1
Grieve, R1
Pocock, SJ1
Simon, T1
Yasuda, S1
Vega, AM1
Brieger, D1
Shaukat, A1
Al-Bustami, M1
Ong, PJ1
Dixon, SR2
Grines, CL3
O'Neill, WW2
Newsome, LT1
Weller, RS1
Gerancher, JC1
Kutcher, MA1
Royster, RL1
Süselbeck, T1
Haghi, D1
Borggrefe, M1
Kaden, JJ1
Asano, T1
Kobayashi, Y1
Fukushima, K1
Iwata, Y1
Kitahara, H1
Ishio, N1
Kuroda, N1
Komuro, I1
Ramsdale, DR1
Rao, A1
Asghar, O1
Ramsdale, KA1
McKay, E1
Cervinka, P1
Bystron, M1
Spacek, R1
Kvasnak, M1
Adhikari, S1
Jakabcin, J1
Alfonso, F3
Hernández, R2
Bethencourt, A1
Martí, V1
López-Mínguez, JR1
Angel, J1
Iñiguez, A2
Morís, C1
Cequier, A1
Sabaté, M2
Escaned, J3
Jiménez-Quevedo, P3
Bañuelos, C3
Suárez, A2
Macaya, C4
Siller-Matula, JM1
Lang, I1
Christ, G3
Jilma, B1
Kleiman, NS1
Graw, J1
Schwenk, W1
Volk, T1
Amasyali, B1
Celik, T1
Iyisoy, A2
Kilic, A1
Isik, E2
Pels, K1
Schwimmbeck, PL1
Rosenthal, P2
Loddenkemper, C1
Dang-Heine, C1
Rauch, U2
Martens, H1
Schultheiss, HP2
Dechend, R1
Deiner, C1
Brilakis, ES1
Lichtenwalter, C1
de Lemos, JA1
Roesle, M1
Obel, O1
Haagen, D1
Saeed, B1
Gadiparthi, C1
Bissett, JK1
Sachdeva, R1
Voudris, VV1
Karyofillis, P1
Kar, B1
Rossen, J1
Fasseas, P1
Berger, P2
Banerjee, S1
Byrne, RA3
Schulz, S3
Mehilli, J9
Iijima, R3
Massberg, S3
Neumann, FJ2
ten Berg, JM5
Schömig, A9
Kastrati, A9
Mirabella, F1
Francaviglia, B1
Di Salvo, ME1
Galassi, AR1
Ussia, GP1
Tamburino, C3
Ben-Dor, I1
Waksman, R7
Wozakowska-Kapłon, B1
Młodnicki, M1
Gutkowski, W1
Rogacka, R1
Chieffo, A2
Michev, I2
Latib, A1
Cosgrave, J2
Montorfano, M1
Carlino, M1
Sangiorgi, GM2
Castelli, A1
Godino, C1
Magni, V1
Aranzulla, TC1
Romagnoli, E1
Bruskina, O1
Pache, J3
Seyfarth, M2
Laugwitz, KL1
Dirschinger, J6
Jähne, J2
Schirren, J2
Rottbauer, W1
Katus, HA1
Bölükbas, S1
Martens, A1
Haverich, A1
Tanajura, LF2
Mattos, LA1
Sousa, AG2
Bonan, R2
Sousa, JE4
van der Giessen, WJ2
Sorop, O1
Serruys, PW3
Peters-Krabbendam, I1
van Beusekom, HM1
Margolis, JR1
Han, Y1
Jing, Q1
Xu, B1
Yang, L1
Shang, X1
Jiang, T1
Li, Z1
Zhang, H1
Li, H1
Qiu, J1
Li, Y1
Chen, X1
Gao, R1
Maldonado, G1
Doi, H1
Maehara, A1
Mintz, GS4
Costa, Jde R1
Sano, K1
Weisz, G3
Dangas, GD2
Lansky, AJ4
Kreps, EM1
Collins, M1
Fahy, M1
Moses, JW7
Leon, MB7
Mehran, R3
Awata, M1
Nanto, S1
Uematsu, M1
Morozumi, T1
Watanabe, T2
Onishi, T1
Iida, O1
Sera, F1
Minamiguchi, H1
Kotani, J2
Nagata, S1
Otake, H2
Shite, J2
Ako, J1
Shinke, T2
Tanino, Y2
Ogasawara, D2
Sawada, T2
Miyoshi, N1
Kato, H1
Koo, BK3
Honda, Y2
Fitzgerald, PJ3
Hirata, K2
Movahed, MR1
Ruiz, M1
Cazares, M1
Pena, A1
Collet, JP1
Hulot, JS1
Silvain, J1
Barthélémy, O1
Beygui, F1
Funck-Brentano, C1
Montalescot, G1
Patel, JH1
Stoner, JA1
Owora, A1
Mathew, ST1
Thadani, U1
Gil, RJ1
Vassilev, D2
Formuszewicz, R1
Rusicka-Piekarz, T1
Doganov, A1
Sakariassen, KS1
Alberts, P1
Fontana, P1
Mann, J1
Bounameaux, H1
Sorensen, AS1
Latif, F1
Heldman, AW1
Hennebry, TA1
Cortese, B1
Picchi, A1
Micheli, A1
Furuta, T1
Yun, SC4
Seong, IW4
Lee, JH4
Lee, NH5
Cho, YH4
Cheong, SS1
Lim, DS2
Yang, JY1
Lee, SG2
Kim, KS1
Seung, KB1
Hong, TJ2
Migliorini, A1
Valenti, R1
Marcucci, R1
Parodi, G1
Giuliani, G1
Buonamici, P1
Cerisano, G1
Carrabba, N1
Gensini, GF1
Abbate, R1
Antoniucci, D2
Chhatriwalla, AK1
Gerber, RT1
Savonitto, S1
D'Urbano, M1
Caracciolo, M1
Barlocco, F1
Mariani, G1
Nichelatti, M1
Klugmann, S1
De Servi, S1
Chun, KJ2
Rhee, KS1
Chae, JK1
Ko, JK2
Park, JH3
Choi, SW3
Jeong, JO1
Jon, S1
Baber, U1
Akhter, M1
Kothari, S1
Sharma, SK1
Kini, A1
García Paredes, T1
Escudero Varela, JC1
Mora Ordóñez, JM1
Fineschi, M2
Grotti, S1
Angioli, P1
Carrera, A1
Ducci, K1
Gori, T2
Falsini, G1
Pierli, C1
Bolognese, L1
Morino, Y2
Kimura, T1
Muramatsu, T1
Ochiai, M1
Noguchi, Y1
Kato, K1
Shibata, Y1
Hiasa, Y1
Doi, O1
Yamashita, T1
Morimoto, T1
Abe, M1
Hinohara, T1
Mitsudo, K2
Serebruany, VL1
Harmsze, AM2
Robijns, K1
van Werkum, JW2
Breet, NJ2
Hackeng, CM2
Ruven, HJ1
Klungel, OH1
de Boer, A1
Deneer, VH2
Stiefelhagen, P1
Stockl, KM1
Le, L1
Zakharyan, A1
Harada, AS1
Solow, BK1
Addiego, JE1
Ramsey, S1
Larson, DM1
Duval, S1
Sharkey, SS1
Solie, C1
Tschautscher, C1
Lips, DL1
Burke, MN1
Steinhubl, S1
Henry, TD1
Sibbing, D2
Braun, S2
Morath, T1
Zeymer, U1
Zahn, R1
Senges, J1
Gitt, A1
Tiroch, KA1
Koch, W1
Roosen-Runge, T1
Chua, D1
Shalansky, SJ1
Legal, MG1
Jung, J1
Batyraliev, TA1
Fettser, DV1
Samko, AN1
Sidorenko, BA1
Venerito, M1
Kandulski, A1
Malfertheiner, P1
Cui, S1
Lü, SZ1
Chen, YD1
He, GX1
Yan, HB1
Meng, LJ1
Song, XT1
Jin, ZN1
Ge, CJ1
Percoco, G3
Monti, M2
Ferrari, F1
Zuffi, A1
Colombo, F2
Kubbajeh, M2
Arcozzi, C1
Frangione, A2
Kozuma, K1
Ota, Y1
Nagai, Y1
Katsuta, Y1
Nozaki, E1
Onodera, T1
Ikari, Y1
Kyo, E1
Yokoi, H1
Nakamura, M1
Carmignani, L1
Picozzi, S1
Stubinski, R1
Casellato, S1
Bozzini, G1
Lunelli, L1
Arena, D1
Lange, CG1
Shin, WY1
Lee, SJ1
Hyon, MS1
Bang, DW1
Choi, YJ2
Lee, BK2
Lee, K1
Park, HK1
Park, CB1
Kim, MK1
Park, WJ1
Lengenfelder, B1
Stoerk, S1
Boes, L1
Strotmann, J1
Ertl, G1
Voelker, W1
Bonz, AW1
Caixeta, A1
Parise, H1
Cristea, E1
Brodie, BR1
Witzenbichler, B1
Guagliumi, G3
Peruga, JZ1
Dudek, D1
Möeckel, M1
Alexopoulos, D1
Xanthopoulou, I1
Karantalis, V1
Mitropoulou, G1
Damelou, A1
Davlouros, P1
Camilleri, E1
Jacquin, L1
Bonello, L1
Bouman, HJ1
Bergmeijer, TO1
Ten Cate, H1
Kuliczkowski, W1
Greif, M1
Gąsior, M1
Kaczmarski, J1
Pres, D1
Poloński, L1
Bhala, N1
Taggar, JS1
Rajasekhar, P1
Banerjee, A1
Lotfi, A1
Cui, J1
Wartak, S1
Columbo, J1
Mulvey, S1
Davis, M1
Schweiger, M1
Giugliano, GR1
Yan, BP1
Ajani, AE5
Clark, DJ1
Duffy, SJ1
Andrianopoulos, N1
Brennan, AL1
Loane, P1
Reid, CM1
Vaquerizo, B1
Serra, A1
Miranda-Guardiola, F1
Martínez, V1
Antoni Gómez-Hospital, J1
Fernández, E1
Ramón Rumoroso, J1
Bosa, F1
Otaegui, I1
Katritsis, DG2
Korovesis, S2
Tzanalaridou, E1
Giazitzoglou, E1
Zografos, T1
Meier, B2
Collet, CA1
Chamié, D1
Siquera, D1
Obregon, J1
Bonaventura, K1
Sonntag, S1
Kleber, FX1
Pant, S1
Neupane, P1
Ramesh, KC1
Barakoti, M1
Pfisterer, M1
Kaiser, C1
Jeger, R1
Gwon, HC1
Hahn, JY1
Park, KW1
Song, YB1
Han, KR1
Choi, JH1
Choi, SH1
Kang, HJ1
Ahn, T1
Yoon, JH1
Chung, WY1
Hur, SH2
Jeon, DW1
Kim, BO1
Park, SH1
Jeon, HK1
Li, ZL1
Zhou, BQ1
Zhu, JH1
Fu, GS1
Bittner, HB1
Lehmann, S1
Rastan, A1
Mohr, FW1
Porto, I1
D'Amario, D1
Crea, F1
Poullis, M1
Hazan, M1
Dean, L1
Castriota, F1
Fucà, G1
Wang, P2
Zhou, S1
Zhou, R1
Liu, G1
Tang, P1
He, J1
Ma, C1
He, Y1
Yang, J1
Jeong, YH2
Park, Y1
Muse, WC1
Kwon, TJ1
Koh, JS1
Hwang, SJ1
Kwak, CH1
Hwang, JY1
Sakurai, R1
Kaneda, H2
Bonneau, HN2
Nagai, R1
Controtto, F1
Scacciatella, P1
Cristofori, R1
Grasso, C1
D'Amico, M1
Pennone, M1
Marra, S1
Jang, JS1
Jin, HY1
Seo, JS1
Yang, TH1
Kim, DK2
Kim, DS1
Seol, SH1
Kim, DI1
Cho, KI1
Kim, BH1
Park, YH1
Je, HG1
Geng, DF1
Jin, DM1
Wu, W1
Deng, J1
Wang, JF1
Einecke, D1
Brodie, B1
Pokharel, Y1
Garg, A1
Kissling, G1
Hansen, C1
Milks, S1
Cooper, M1
McAlhany, C1
Stuckey, T1
Kim, JM1
Park, DS1
Lee, KH1
Sim, DS1
Yoon, HJ1
Yoon, NS1
Kim, KH2
Park, HW1
Ahn, Y2
Cho, JG1
Park, JC1
Kang, JC1
Itagaki, BK1
Brar, SS1
Pinnow, E2
Cheneau, E2
Leborgne, L2
Dieble, R1
Bui, AB1
Satler, LF4
Pichard, AD3
Kent, KK1
Lindsay, J2
Kamishirado, H1
Inoue, T2
Mizoguchi, K1
Uchida, T2
Nakata, T1
Sakuma, M2
Takayanagi, K1
Morooka, S1
Silber, S4
Talbert, RL1
Spinler, SA3
Nappi, JM1
Bottorff, MB1
Krötz, F1
Schiele, TM1
Zahler, S1
König, A1
Rieber, J1
Kantlehner, R1
Pöllinger, B1
Dühmke, E1
Theisen, K1
Sohn, HY1
Klauss, V1
Ziegler, S1
Maca, T1
Alt, E1
Speiser, W1
Schneider, B1
Minar, E1
Sick, P1
Hüttl, T1
Niebauer, J2
Thiele, H2
Lauer, B1
Hambrecht, R1
Hentschel, B1
Schuler, G2
Wohlgemuth, WA1
Bohndorf, K1
Baumgart, D1
Hehrlein, C1
Meinertz, T1
Mügge, A1
Rutsch, W2
vom Dahl, J1
Toutouzas, K1
Di Mario, C4
Falotico, R1
Takagi, T1
Stankovic, G1
Albiero, R1
Corvaja, N1
Fujita, M1
Mizuno, K1
Ho, M1
Tsukahara, R1
Miyamoto, A1
Miki, O1
Ishii, K1
Miwa, K1
Shim, WH1
Ho, DS1
Raizner, AE2
Choi, D1
Lam, R1
Weissman, NJ1
Cha, DH1
Malik, IA1
Wolfram, R1
Porrazzo, M1
Kent, KM1
Bass, TA1
Tani, S1
Kanmatsuse, K1
Bouvier, JL1
Roquebert, PO1
Macaluso, G1
Commeau, P1
Comet, B1
Lafont, A1
Camoin, L1
Walter, U1
Eigenthaler, M2
Grise, MA1
Reilly, JP1
Tobis, JM1
Takano, Y1
Currier, JW1
Kobashigawa, JA1
Yeung, A1
Teirstein, PS3
Pekdemir, H1
Cin, VG1
Camsari, A1
Cicek, D1
Akkus, MN1
Doven, O1
Parmaksiz, T1
Schühlen, H4
Dotzer, F3
Bollwein, H3
Volmer, C1
Gawaz, M1
Berger, PB3
Jaster, M1
Fuster, V1
Pauschinger, M1
Tran, QV1
Janssen, D1
Hinkelbein, W1
Schwimmbeck, P1
Khambekar, SK1
Kovac, J1
Gershlick, AH3
Song, JM1
Han, KH2
Kang, DH1
Song, JK1
Topol, EJ4
Ludwig, J1
Holmes, DR4
Spanos, V1
Louvard, Y2
Desmedt, B1
Von Scheidt, W1
Gurbel, PA2
Samara, WM1
Bliden, KP1
Matetzky, S1
Shenkman, B1
Guetta, V1
Shechter, M1
Beinart, R1
Bienart, R1
Goldenberg, I1
Novikov, I1
Pres, H1
Savion, N1
Varon, D1
Hod, H1
SoRelle, R1
Sekiguchi, M1
Hoshizaki, H1
Adachi, H1
Ohshima, S1
Taniguchi, K1
Kurabayashi, M1
Hashiguchi, M1
Ohno, K1
Nakazawa, R1
Kishino, S1
Mochizuki, M1
Shiga, T1
Sawhney, N1
Kuntz, RE4
Popma, JJ5
Bachinsky, W1
Bass, T1
DeMaio, S1
Fry, E1
Cohen, DJ2
Bakhai, A1
Shi, C1
Githiora, L1
Lavelle, T1
Berezin, RH1
Carrozza, JP1
Zidar, JP1
Vivekananthan, DP1
Chew, DP1
Zidar, FJ1
Chan, AW1
Moliterno, DJ2
Ellis, SG2
Casselman, FP1
Meco, M1
Dom, H1
Foubert, L1
Van Praet, F1
Vanermen, H1
Weintraub, WS1
Brener, SJ2
Lincoff, AM1
Steinhubl, SR2
Wolski, KE1
Akbulut, M1
Ozbay, Y1
Karaca, I1
Ilkay, E1
Gundogdu, O1
Arslan, N1
Sianos, G2
de Scheerder, I1
van den Heuvel, PA1
Glogar, HD1
Materne, PH1
Veldhof, S1
Vonhausen, H1
Otto-Terlouw, PC1
Rampp, T1
Block, M1
Ohman, EM1
Harrington, RA1
Grines, C1
Weitz, JI1
Imoto, Y1
Ozeki, Y1
Ozaki, Y2
Hikichi, Y1
Node, K1
Melero, JM1
Porras, C1
Such, M1
Olalla, E1
Alonso, J1
Dibra, A2
von Beckerath, N1
Berger, PP1
Cox, N1
Fitzpatrick, M1
Douglas, J1
Lambert, C1
Mooney, M1
Yakubov, S1
von Mach, MA1
Eich, A1
Weilemann, LS1
Münzel, T1
Nikfardjam, M1
Huber-Beckmann, R1
Gottsauner-Wolf, M1
Glogar, D2
Binder, BR1
Wojta, J2
Huber, K2
Maresta, A2
Balducelli, M1
Latini, R1
Bernardi, G1
Moccetti, T1
Sosa, C1
Barlera, S1
Varani, E2
Ribeiro da Silva, EE1
Monici Preti, A1
Maggioni, AP1
von Heymann, C1
Schoenfeld, H1
Sander, M1
Ziemer, S1
Grubitzsch, H1
Spies, C1
Karvouni, E1
Mehta, RH1
Harjai, KJ1
Boura, J1
O'Neill, W1
Benito, B1
Masotti, M1
Betriu, A1
Sick, PB1
Brosteanu, O1
Ulrich, M1
Busch, I1
Hadamitzky, M1
Baum, H1
Biancari, F1
Juvonen, T1
Chen, WH1
Kaul, U1
Leung, SK1
Lau, YK1
Tan, HC1
Leung, AW1
Lee, MK1
Li, SK1
Ng, W1
Lee, PY1
Lam, KF1
Tse, HF1
Lau, CP1
Suzuki, J1
Hosokawa, G1
Tanaka, S1
Hiroe, Y1
Saito, S1
Lengyel, M1
Bull, S1
Chahal, N1
McKenna, CJ1
Kramer, HJ1
Tepe, G1
Muschick, P1
Laule, M1
Reddig, F1
Claussen, CD1
Dinkelborg, LM1
Tielemans, H1
Wehrmann, M1
Duda, SH1
Biondi-Zoccai, GG1
Agostoni, P1
Iakovou, I1
Grube, E2
Reimers, B2
Goktekin, O1
Tassanawiwat, W1
Kurşaklioğlu, H1
Köz, C1
Ide, T1
Yildirim, V1
Töre, HF1
Demirtaş, E1
Urban, P1
Guyon, P1
Lotan, C1
Schofer, J2
Seth, A1
Berge, C1
Deme, M1
Stoll, HP1
Templin, C1
Schaefer, A1
Stumme, B1
Drexler, H1
von Depka, M1
Makkar, K1
Wilensky, RL3
Julien, MB1
Herrmann, HC1
Lee-Wong, M1
Gadhvi, D1
Resnick, D1
Spertus, JA1
Kettelkamp, R1
Vance, C1
Decker, C1
Jones, PG1
Rumsfeld, JS1
Messenger, JC1
Khanal, S1
Peterson, ED1
Bach, RG1
Krumholz, HM1
Hausleiter, J1
Ishikawa, T2
Mutoh, M2
Fuda, Y2
Sakamoto, H2
Okada, H2
Higashitani, M2
Nakano, Y2
Yamaguchi, J1
Enta, K1
Satoh, T1
Imai, K2
Horie, T2
Mochizuki, S2
Nikas, DN1
Kalef-Ezra, J1
Katsouras, CS1
Tsekeris, P1
Bozios, G1
Pappas, C1
Naka, KK1
Kotsia, A1
Papamichael, N1
Sideris, DA1
Michalis, LK1
Gruberg, L1
Beyar, R1
Tantry, US1
Gaku, N1
Kengo, T1
Aoki, J1
Onuma, Y1
Yamamoto, H1
Higashikuni, Y1
Nakajima, H1
Hara, K1
McAllister, RK1
Dehmer, GJ1
Meyer, TA1
Tsurusaki, T1
Ohta, M1
Broad, L1
Lee, T1
Conroy, M1
Bolsin, S1
Orford, N1
Black, A1
Birdsey, G1
Matsumoto, D1
Paredes, OL1
Yokoyama, M1
Gochi, T1
Umeda, H1
Yoshida, N1
Maekawa, H1
Watanabe, K1
Okada, T1
Katoh, T1
Asai, T1
Tani, T1
Yokoya, M1
Murakami, Y1
Matsushita, T1
Shimizu, T1
Hiramitsu, S1
Murohara, T1
Nomura, M1
Morimoto, S1
Hishida, H1
Richardson, G1
Wiper, AJ1
Roberts, DH1
Antoniou, S1
Rothman, MT1
Wenaweser, P1
Billinger, M1
Cook, S1
Togni, M1
Haeberli, A1
Hess, OM1
Schäfer, A1
Bauersachs, J1
Rabbat, MG1
Bavry, AA1
Eltchaninoff, H1
Funck, F1
Grinius, V1
Navickas, R1
Unikas, R1
Daemen, J1
Tanimoto, S1
García-García, HM1
Kukreja, N1
van de Sande, M1
de Jaegere, PP1
van Domburg, RT1
Mishkel, G1
Bartorelli, AL1
Trabattoni, D1
Galassi, A1
Serdoz, R1
Sheiban, I1
Piovaccari, G2
Zimarino, M1
Benassi, A2
Sangiorgio, P1
Chierchia, S1
Finn, AV1
Joner, M1
Nakazawa, G1
Kolodgie, F1
Newell, J1
John, MC1
Gold, HK1
Virmani, R1
Hacquard, M1
Angioï, M1
Lecompte, T1
Vigneron, C1
Tamura, A1
Shinozaki, K1
Kotoku, M1
Yano, S1
Kadota, J1
Majdoub, MA1
Sauguet, A1
Tchetche, D1
Ducrocq, G1
Himbert, D1
Aubry, P1
Feldman, LJ1
Juliard, JM1
Gladding, P1
Webster, M1
Angiolillo, DJ1
Hernández-Antolín, R1
SanMartín, M1
Gómez-Hospital, JA1
Moreno, R1
Fernández, C1
Fernández-Avilés, F1
Marzocchi, A1
Saia, F1
Manari, A1
Aurier, E1
Cremonesi, A1
Magnavacchi, P1
Guastaroba, P1
Grilli, R1
Hoppe, UC1
Erdmann, E1
Brennan, DM1
Asamasu-Sato, S1
Mita, M1
Ogawa, R1
Isaka, M1
Saito, M1
Jang, S1
Chi, HS1
Unverdorben, M1
Degenhardt, R1
Wiemer, M1
Horstkotte, D1
Schneider, H1
Nienaber, C1
Bocksch, W1
Gross, M1
Boxberger, M1
Vallbracht, C1
Roy, P1
Torguson, R1
Okabe, T1
Pinto Slottow, TL1
Steinberg, DH1
Smith, K1
Xue, Z1
Dawkins, KD1
Banning, AP2
Zmudka, K1
Thuesen, L1
Hauptman, K1
Marco, J1
Buellesfeld, L1
Koglin, J1
Russell, ME1
Mood, GR1
Bhatia, A1
Nicholls, H1
Jeong, JW1
Ahn, TH1
Kang, WC1
Park, CG1
Nam, CW1
Bae, JH1
Kim, KY1
Oh, SK1
Katsaros, KM1
Speidl, WS1
Kastl, SP1
Zorn, G1
Maurer, G1
Sheehy, O1
LeLorier, J1
Rinfret, S1
Suissa, S1
Ryding, AD1
Bertrand, OF1
Faurie, B1
Larose, E1
Nguyen, CM1
Gleeton, O1
Déry, JP1
Noël, B1
Proulx, G1
Roy, L1
Costerousse, O1
De Larochellière, R1
Rodés-Cabau, J1
Krucoff, MW1
Petersen, JL1
Hasselblad, V1
Garg, J1
Turco, MA1
Simonton, CA1
Verheye, S1
Dubois, CL1
Gammon, R1
Batchelor, WB1
O'Shaughnessy, CD1
Hermiller, JB1
Buchbinder, M1
Ndrepepa, G1
Hutten, BA1
Kelder, JC1
Verheugt, FW1
Plokker, HW1
Dzavik, V1
Penn, IM1
Catellier, D1
Buller, CE1
Makoni, SN1
Limpijankit, T1
Yock, PG1

Clinical Trials (69)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902]25 participants (Actual)Observational [Patient Registry]2022-02-03Completed
A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724]Phase 4630 participants (Actual)Interventional2010-03-31Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]Phase 48,709 participants (Actual)Interventional2007-06-30Completed
Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044]120 participants (Anticipated)Interventional2015-11-30Active, not recruiting
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423]Phase 2113 participants (Actual)Interventional2006-05-31Completed
Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020]1,240 participants (Anticipated)Observational2011-11-30Not yet recruiting
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319]Phase 31,606 participants (Actual)Interventional2011-06-30Active, not recruiting
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]Phase 3220 participants (Actual)Interventional2009-04-30Completed
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904]9,284 participants (Actual)Observational2013-06-19Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.)
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066]Phase 4100 participants (Anticipated)Interventional2016-01-31Recruiting
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953]Phase 4190 participants (Actual)Interventional2010-01-31Active, not recruiting
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940]Phase 4310 participants (Anticipated)Interventional2010-01-31Recruiting
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878]Phase 4130 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424]100 participants (Anticipated)Observational [Patient Registry]2016-05-31Recruiting
Platelet Function in Resuscitated Patients[NCT02914795]99 participants (Actual)Observational2015-06-30Completed
The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions[NCT00247208]Phase 380 participants (Actual)Interventional2005-05-31Completed
Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)[NCT00133237]Phase 4607 participants (Actual)Interventional2005-07-31Completed
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578]Phase 42,077 participants (Actual)Interventional2006-06-30Completed
Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study[NCT02192840]Phase 4243 participants (Actual)Interventional2010-10-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625]78 participants (Actual)Observational2011-11-30Terminated (stopped due to As recruitment rate was lower than anticipated)
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]889 participants (Actual)Interventional2013-06-30Terminated (stopped due to Ethics Committe decision)
Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927]Phase 4486 participants (Anticipated)Interventional2007-12-31Completed
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]Phase 33,602 participants (Actual)Interventional2005-03-31Completed
Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014]1,000 participants (Anticipated)Observational2006-01-31Completed
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607]Phase 41,466 participants (Anticipated)Interventional2008-06-30Active, not recruiting
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]31 participants (Actual)Interventional2014-09-30Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237]70 participants (Actual)Interventional2016-06-30Completed
LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651]69 participants (Anticipated)Observational2016-05-31Enrolling by invitation
Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594]100 participants (Anticipated)Observational2020-10-01Recruiting
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]Phase 42,022 participants (Actual)Interventional2003-03-31Completed
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054]Phase 44,570 participants (Actual)Interventional2005-11-30Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]Phase 4800 participants (Actual)Interventional2003-06-30Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]Phase 460 participants (Actual)Interventional2004-10-31Completed
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]159 participants (Actual)Interventional2006-05-31Completed
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]Phase 42,505 participants (Actual)Interventional2008-08-31Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]120 participants (Anticipated)Interventional2014-08-31Not yet recruiting
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]Phase 4150 participants (Actual)Interventional2007-09-30Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]Phase 4190 participants (Anticipated)Interventional2010-06-30Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]Phase 4200 participants (Anticipated)Interventional2005-03-31Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]Phase 420 participants (Actual)Interventional2009-06-30Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]Phase 480 participants (Actual)Interventional2008-11-30Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]Phase 3200 participants (Actual)Interventional2005-06-30Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]100 participants (Anticipated)Observational2015-09-30Not yet recruiting
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]Phase 330 participants (Anticipated)Interventional2009-04-30Recruiting
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]Phase 4200 participants (Actual)Interventional2006-01-31Completed
ABILITY Diabetes Global[NCT04236609]3,050 participants (Actual)Interventional2020-06-15Active, not recruiting
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]179 participants (Actual)Interventional2003-01-31Completed
[NCT00000614]Phase 30 participants Interventional1998-09-30Completed
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273]18,000 participants (Actual)Observational2010-08-25Completed
BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985]Phase 3440 participants (Anticipated)Interventional2015-07-31Recruiting
Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938]Phase 260 participants (Anticipated)Interventional2022-11-30Recruiting
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]1,800 participants (Anticipated)Observational [Patient Registry]2018-11-21Not yet recruiting
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931]9,501 participants (Actual)Interventional2019-07-01Active, not recruiting
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654]Phase 360 participants (Actual)Interventional2010-09-30Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]Phase 430 participants (Anticipated)Interventional2007-11-30Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]Phase 477 participants (Anticipated)Interventional2006-08-31Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]60 participants (Actual)Interventional2008-05-31Completed
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]33 participants (Actual)Observational2014-12-31Completed
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561]44 participants (Actual)Interventional2008-04-30Completed
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]Phase 460 participants (Actual)Interventional2012-04-30Completed
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]Phase 450 participants (Actual)Interventional2017-02-16Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]0 participants (Actual)Observational2010-11-30Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]8 participants (Actual)Interventional2013-09-30Completed
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]Phase 480 participants (Actual)Interventional2009-05-31Completed
Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries[NCT00165035]Phase 31,701 participants (Actual)Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years

Interventionparticipants (Number)
E-ZES61
C-SES75

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

,
Interventionparticipants (Number)
Total death and large non-fatal myocardial infarctTotal death and non-fatal myocardial infarctionsCardiac death and large non-fatal MICardiac death and non-fatal MITarget lesion revascularizationStrokeBleeding events
C-SES25536017428215672184
E-ZES22533115726524977201

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel4
Placebo5

Incidence of Major Bleeding Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel1
Placebo0

Vein Graft Angiographic Patency

Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery

Interventionpercentage (Number)
75mg Clopidogrel94.3
Placebo93.2

Vein Graft Intimal Area

IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery

Interventionmm (Mean)
75mg Clopidogrel4.1
Placebo4.5

Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis

(NCT02914795)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Non-resuscitated Myocardial Infarction0
Resuscitated Myocardial Infarction3

Platelet Inhibition Measured With Optical Aggregometry

Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3

InterventionAU*min (Median)
Non-resuscitated Myocardial Infarction109
Resuscitated Myocardial Infarction253.8

Device Time

This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant91.2

Fluoroscopy Duration

This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant41.2

Number of Participants With Acute Procedural Success Rate

Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionParticipants (Count of Participants)
MitraClip Implant39

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant8.3

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant6.1

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant0.0

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
MitraClip Implant91.5

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
MitraClip Implant85.3

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
MitraClip Implant96.1

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
MitraClip Implant100

Post-procedure Hospital Stay

This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionDays (Mean)
MitraClip Implant3.4

Post-procedure Intensive Care Unit (ICU)/Critical Care Unit (CCU)/Post-anesthesia Care Unit (PACU) Duration

ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

InterventionHours (Mean)
MitraClip Implant62.1

Procedure Time

This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMinutes (Mean)
MitraClip Implant133.5

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months

InterventionMeters (Mean)
MitraClip Implant329.9

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days

InterventionMeters (Mean)
MitraClip Implant297.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months

InterventionMeters (Mean)
MitraClip Implant324.3

Six Minute Walking Distance

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline

InterventionMeters (Mean)
MitraClip Implant271.0

Total Contrast Volume

This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

InterventionMilliliters (Mean)
MitraClip Implant10.6

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 12 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months

Interventionscores on a scale (Mean)
Baseline12 monthsDifference (12 months - Baseline)
MitraClip Implant51.130.2-20.9

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 30 Days

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days

Interventionscores on a scale (Mean)
Baseline30 daysDifference (30 days - Baseline)
MitraClip Implant50.426.4-24.0

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 6 Months

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months

Interventionscores on a scale (Mean)
Baseline6 monthsDifference (6 months - Baseline)
MitraClip Implant49.528.0-21.5

Duration of Rehospitalization

(NCT01301625)
Timeframe: 30 days

InterventionDays (Mean)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant8.418.382.877.44

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant148.5132.4

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant140.4138.8

Left Atrial Volume

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant141.7141.8

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant161.1150.1

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant152.9148.2

Left Ventricle End Diastolic Volume (LVEDV)

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliters (Mean)
BaselineDischarge
MitraClip Implant158.2151.3

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionpercent (Mean)
Baseline12 Months
MitraClip Implant46.947.4

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionpercent (Mean)
Baseline30 Days
MitraClip Implant48.446.5

Left Ventricular Ejection Fraction (LVEF)

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionpercent (Mean)
BaselineDischarge
MitraClip Implant47.244.6

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant97.891.7

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant88.589.0

Left Ventricular End Systolic Volume (LVESV)

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionMilliliter (Mean)
BaselineDischarge
MitraClip Implant93.393.2

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant6.05.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Diastole (LVIDd)

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant5.95.7

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm (Mean)
Baseline12 Months
MitraClip Implant4.64.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm (Mean)
Baseline30 Days
MitraClip Implant4.54.5

Left Ventricular Internal Diameter End Systole (LVIDs)

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm (Mean)
BaselineDischarge
MitraClip Implant4.54.4

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventioncm^2 (Mean)
Baseline12 Months
MitraClip Implant3.82.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventioncm^2 (Mean)
Baseline30 Days
MitraClip Implant3.52.3

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventioncm^2 (Mean)
BaselineDischarge
MitraClip Implant3.52.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionmmHg (Mean)
Baseline12 Months
MitraClip Implant2.33.4

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionmmHg (Mean)
Baseline30 Days
MitraClip Implant2.33.5

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionmmHg (Mean)
BaselineDischarge
MitraClip Implant2.33.7

Number of Participants at Discharge Facility

This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days

InterventionParticipants (Count of Participants)
HomeHome with home health careSkilled nursing facilityNursing homeDeathOther
MitraClip Implant7041021

Number of Participants With 0, 1, 2, and 3 MitraClip Devices Implanted

This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)

InterventionParticipants (Count of Participants)
0 Mitra Clip devices1 Mitra Clip devices2 Mitra Clip devices3 Mitra Clip devices
MitraClip Implant141351

Number of Participants With Mitral Valve Surgery

Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationDevice failure
MitraClip Implant11

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant21515730

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant126251250

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant020241240

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant13822931

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
0: None1+:Mild2+: Moderate3+: Moderate-to-Severe4+: SevereNot Evaluable
MitraClip Implant00022550

Number of Participants With Second Intervention to Place an Additional MitraClip Device

Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months

InterventionParticipants (Count of Participants)
Recurring mitral regurgitationSingle leaflet device attachment (SLDA)
MitraClip Implant21

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant52.542.52.52.5

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant36.244.915.92.9

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant33.356.78.31.7

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline

Interventionpercentage of participants (Number)
NYHA INYHA IINYHA IIINYHA IV
MitraClip Implant2.626.951.319.2

Rate of Patients Rehospitalized

Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
All re-hospitalizationsHeart Failure-related re-hospitalizationsOther cardiac-related re-hospitalizationsOther non-cardiac-related re-hospitalizations
MitraClip Implant35101122

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months

InterventionPercentage (Mean)
Baseline12 Months
MitraClip Implant44.636.8

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days

InterventionPercentage (Mean)
Baseline30 Days
MitraClip Implant40.515.2

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

InterventionPercentage (Mean)
BaselineDischarge
MitraClip Implant38.925.8

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months

Interventionml (Mean)
Baseline12 Months
MitraClip Implant49.873.3

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days

Interventionml (Mean)
Baseline30 Days
MitraClip Implant61.925.6

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Interventionml (Mean)
BaselineDischarge
MitraClip Implant55.525.1

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin379
Pharmacology Arm - Unfractionated Heparin377

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin98
Pharmacology Arm - Unfractionated Heparin99

Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin166
Pharmacology Arm - Unfractionated Heparin218

Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding

Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin89
Pharmacology Arm - Unfractionated Heparin149

Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis

Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent181
Stent Arm - Bare Metal Stent59

Stent Arm - Ischemic Target Lesion Revascularization

Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent98
Stent Arm - Bare Metal Stent54

Stent Arm - Segment Binary Angiographic Restenosis

Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent102
Stent Arm - Bare Metal Stent76

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

InterventionUS dollars (Mean)
Oral Sirolimus + Bare Metal Stent5483
Drug Eluting Stents7658.2

Target Vessel Revascularization (TVR)

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Interventionvessels (Number)
Oral Sirolimus + Bare Metal Stent14
Drug Eluting Stents15

Major Adverse Cardiovascular Events (MACCE)

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

,
Interventionparticipants (Number)
MACCEDeathAcute Myocardial InfarctionStroke
Drug Eluting Stents15791
Oral Sirolimus + Bare Metal Stent9360

Percent Stent Coverage

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
85% up to 90% stent coverage90% up to 95% stent coverage95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent010
Non-diabetic Patients Receiving the Resolute Stent131

Reviews

41 reviews available for ticlopidine and Coronary Restenosis

ArticleYear
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule;

2017
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro

2014
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2008, Jun-17, Volume: 51, Issue:24

    Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Co

2008
Coronary artery stents: II. Perioperative considerations and management.
    Anesthesia and analgesia, 2008, Volume: 107, Issue:2

    Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel;

2008
[Drug-eluting stents: implications for modern coronary revascularization].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor

2009
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
    The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr

2009
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
    Future cardiology, 2009, Volume: 5, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans;

2009
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp

2010
[Dilemma between gastroprotection and cardiovascular prevention].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44

    Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases;

2010
Is prasugrel more effective than clopidogrel at preventing future cardiac events?
    JAAPA : official journal of the American Academy of Physician Assistants, 2011, Volume: 24, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggr

2011
Personalized antiplatelet therapy: review of the latest clinical evidence.
    Current cardiology reports, 2011, Volume: 13, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease;

2011
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
    BMJ (Clinical research ed.), 2011, Jul-21, Volume: 343

    Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease

2011
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 7 Suppl K

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco

2011
Cilostazol and primary-PCI: mirage or good alternative?
    Current vascular pharmacology, 2012, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol;

2012
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
    Clinical cardiology, 2012, Volume: 35, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art

2012
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
    International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin

2013
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com

2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil

2012
Controversies in the use & implementation of drug-eluting stent technology.
    The Indian journal of medical research, 2012, Volume: 136, Issue:6

    Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa

2012
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
    Zeitschrift fur Kardiologie, 2002, Volume: 91, Issue:6

    Topics: Brachytherapy; Cell Division; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coated Materials, B

2002
Combination antiplatelet therapy: implications for pharmacists.
    Pharmacotherapy, 2002, Volume: 22, Issue:10

    Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H

2002
[Endovascular brachytherapy to prevent restenosis after angioplasty].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2003, Volume: 175, Issue:2

    Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Brachyth

2003
Sirolimus-eluting stents: a review of experimental and clinical findings.
    Zeitschrift fur Kardiologie, 2002, Volume: 91 Suppl 3

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography

2002
[Anti thrombotic therapy after coronary thrombolysis].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari

2003
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
    European heart journal, 2004, Volume: 25, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona

2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Circulation, 2004, Aug-24, Volume: 110, Issue:8

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl

2004
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindic

2004
[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
    Revista espanola de cardiologia, 2005, Volume: 58, Issue:6

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopi

2005
[Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)].
    Orvosi hetilap, 2005, Sep-11, Volume: 146, Issue:37

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Coumarins; Drug Ther

2005
[PCI: state of the art].
    Nihon Geka Gakkai zasshi, 2006, Volume: 107, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Humans; Japan; P

2006
Aspirin and clopidogrel resistance: consideration and management.
    Journal of interventional cardiology, 2006, Volume: 19, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topi

2006
Understanding and minimizing late thrombosis of drug-eluting stents.
    Cleveland Clinic journal of medicine, 2007, Volume: 74, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Humans; Pla

2007
[The best of interventional cardiology in 2006].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100 Spec No 1

    Topics: Angioplasty, Balloon, Coronary; Cardiology; Cardiovascular Diseases; Clinical Trials as Topic; Clopi

2007
[Stents in interventional cardiology].
    Medicina (Kaunas, Lithuania), 2007, Volume: 43, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop

2007
[Cardiology 2007].
    Deutsche medizinische Wochenschrift (1946), 2007, Jun-22, Volume: 132, Issue:25-26

    Topics: Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Cholesterol; Clopidogrel; Coronary Ar

2007
Clopidogrel and risk for acute coronary events.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Human

2007
Mortality benefit from unrestricted access to clopidogrel: too good to be true?
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Feb-12, Volume: 178, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Restenosis; Drug Prescriptions; Health

2008
Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:6

    Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Catheterization; Clopidogrel

2001
The WRIST series--what have we learnt?
    Herz, 2002, Volume: 27, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Brachytherapy; Clopidogrel; Cohort Studies; Coronary Restenosi

2002
[Intracoronary radiation therapy in controlled and open clinical trials with afterloading systems and "hot" balloon catheters. Analysis of 6,692 patients].
    Herz, 2002, Volume: 27, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Beta Particles; Brachytherapy; Clinical Trials as Topic; Clopi

2002

Trials

77 trials available for ticlopidine and Coronary Restenosis

ArticleYear
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
    The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl

2013
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Journal of the American College of Cardiology, 2014, Feb-18, Volume: 63, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Mid

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    American heart journal, 2014, Volume: 167, Issue:2

    Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D

2014
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2014
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:1

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C

2014
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu

2015
Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
    Current medical research and opinion, 2015, Volume: 31, Issue:3

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Monitoring; Drug-Eluting Stent

2015
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona

2015
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co

2015
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
    Scientific reports, 2015, Sep-09, Volume: 5

    Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies;

2015
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    JACC. Cardiovascular interventions, 2016, 09-12, Volume: 9, Issue:17

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C

2016
Prevalence and Predictors of Early Discontinuation of Dual-Antiplatelet Therapy After Drug-Eluting Stent Implantation in Korean Population.
    The American journal of cardiology, 2016, Nov-15, Volume: 118, Issue:10

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationshi

2016
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona

2017
Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:10

    Topics: Adult; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Re

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
    Journal of the American College of Cardiology, 2009, Mar-17, Volume: 53, Issue:11

    Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting

2009
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual
    American heart journal, 2009, Volume: 157, Issue:4

    Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Dose-Response Relations

2009
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Journal of the American College of Cardiology, 2009, May-12, Volume: 53, Issue:19

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coron

2009
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate

2009
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
    British journal of anaesthesia, 2010, Volume: 104, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C

2010
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
    The American journal of cardiology, 2010, Jan-15, Volume: 105, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete

2010
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
    JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea

2010
Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Restenosis; Dose-Respons

2010
[Implantation of the paclitaxel-eluting stent Apollo in patients with stable angina pectoris: long-term angiographic and clinical results].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:8

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2010
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment
    American heart journal, 2010, Volume: 160, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Vessels

2010
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
    Journal of the American College of Cardiology, 2011, Mar-15, Volume: 57, Issue:11

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M

2011
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combi

2011
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Circulation, 2011, Apr-26, Volume: 123, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosi

2011
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:15

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Di

2011
Spot drug-eluting stenting for long coronary stenoses: long-term results of a randomized clinical study.
    Journal of interventional cardiology, 2011, Volume: 24, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary

2011
Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents.
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:10

    Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug-Eluting Stents; Fema

2011
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels

2012
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
    European heart journal, 2013, Volume: 34, Issue:12

    Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy

2013
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
    Circulation, 2002, Aug-13, Volume: 106, Issue:7

    Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm

2002
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
    American heart journal, 2002, Volume: 144, Issue:2

    Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy

2002
Sustained platelet activation following intracoronary beta irradiation.
    The American journal of cardiology, 2002, Dec-15, Volume: 90, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido

2002
Sarpogrelate treatment reduces restenosis after coronary stenting.
    American heart journal, 2003, Volume: 145, Issue:3

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography;

2003
A paclitaxel-eluting stent for the prevention of coronary restenosis.
    The New England journal of medicine, 2003, Apr-17, Volume: 348, Issue:16

    Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography;

2003
A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation.
    Heart and vessels, 2003, Volume: 18, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Admini

2003
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    The New England journal of medicine, 2004, Jan-15, Volume: 350, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
    Platelets, 2004, Volume: 15, Issue:2

    Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Coronary Restenosis; Female; Humans; Ma

2004
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:7

    Topics: Aged; Cilostazol; Coronary Restenosis; Coronary Stenosis; Equipment Design; Female; Follow-Up Studie

2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary

2004
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Coronary Restenosis; Cost-Bene

2004
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
    Coronary artery disease, 2004, Volume: 15, Issue:6

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C

2004
Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo i
    Journal of the American College of Cardiology, 2004, Aug-04, Volume: 44, Issue:3

    Topics: Aged; Aspirin; Brachytherapy; Clopidogrel; Coronary Angiography; Coronary Restenosis; Europe; Female

2004
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
    Journal of the American College of Cardiology, 2004, Oct-06, Volume: 44, Issue:7

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease

2004
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Circulation, 2004, Dec-14, Volume: 110, Issue:24

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Arter

2004
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
    Circulation, 2004, Dec-21, Volume: 110, Issue:25

    Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary S

2004
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2005, Volume: 64, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography;

2005
Comparison of cilostazol and clopidogrel after successful coronary stenting.
    The American journal of cardiology, 2005, Apr-01, Volume: 95, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female;

2005
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
    American heart journal, 2005, Volume: 149, Issue:4

    Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl

2005
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:10

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co

2005
Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
    International journal of cardiology, 2005, Oct-20, Volume: 105, Issue:1

    Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Reste

2005
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary inte
    American heart journal, 2006, Volume: 151, Issue:6

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Angio

2006
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3

    Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb

2007
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; El

2007
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Corona

2007
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor

2007
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
    International journal of cardiology, 2008, May-07, Volume: 126, Issue:1

    Topics: Aged; Coronary Restenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans;

2008
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    European heart journal, 2007, Volume: 28, Issue:16

    Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death,

2007
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
    The Journal of invasive cardiology, 2007, Volume: 19, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Drug T

2007
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
    The American journal of cardiology, 2007, Aug-15, Volume: 100, Issue:4

    Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno

2007
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2007, Volume: 96, Issue:11

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female;

2007
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    European heart journal, 2007, Volume: 28, Issue:21

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2007
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:1

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
    Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Journal of the American College of Cardiology, 2008, Apr-22, Volume: 51, Issue:16

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium All

2008
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
    The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9

    Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Clopidogr

2008
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
    Circulation, 2001, Apr-24, Volume: 103, Issue:16

    Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere

2001
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA).
    American heart journal, 2001, Volume: 142, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Restenosis; Drug Therapy, Combin

2001
Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis.
    Circulation, 2002, May-28, Volume: 105, Issue:21

    Topics: Blood Vessel Prosthesis Implantation; Brachytherapy; Cohort Studies; Coronary Restenosis; Disease Pr

2002

Other Studies

155 other studies available for ticlopidine and Coronary Restenosis

ArticleYear
    Drug metabolism and personalized therapy, 2021, 01-01, Volume: 37, Issue:2

    Topics: Aspirin; Case-Control Studies; Clopidogrel; Coronary Restenosis; Cytochrome P-450 CYP2C19; Drug-Elut

2021
Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019, Aug-09, Volume: 15, Issue:6

    Topics: Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Humans; Percutaneous Coronary I

2019
Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.
    International journal of cardiology, 2017, Aug-01, Volume: 240

    Topics: Adenosine; Animals; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Hy

2017
The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.
    Acta pharmacologica Sinica, 2018, Volume: 39, Issue:2

    Topics: Aged; Asian People; Aspirin; China; Cilostazol; Clopidogrel; Coronary Restenosis; Data Interpretatio

2018
Antiplatelet Monotherapy After Percutaneous Coronary Intervention. Contemporary Long-term Outcomes and Matched Comparison With Routine Clinical Practice.
    Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:11

    Topics: Aged; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Interventi

2018
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator.
    Advances in therapy, 2019, Volume: 36, Issue:9

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans

2019
Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation.
    Chinese medical journal, 2013, Volume: 126, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle A

2013
[Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2013, Volume: 19, Issue:1

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2013
A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon.
    The Journal of invasive cardiology, 2013, Volume: 25, Issue:5

    Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2013
High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:5

    Topics: Aged; Angina, Stable; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Humans; Male;

2013
[The CHAMPION PHOENIX study].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D

2013
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
    Circulation, 2014, Sep-09, Volume: 130, Issue:11 Suppl 1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C

2014
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
    Circulation, 2014, Sep-09, Volume: 130, Issue:11 Suppl 1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C

2014
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
    Circulation, 2014, Sep-09, Volume: 130, Issue:11 Suppl 1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C

2014
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
    Circulation, 2014, Sep-09, Volume: 130, Issue:11 Suppl 1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C

2014
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem

2015
Stent selection and antiplatelet therapy duration: one size does not fit all.
    Journal of the American College of Cardiology, 2015, Mar-03, Volume: 65, Issue:8

    Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage;

2015
A multidisciplinary approach in early stent thrombosis: Insights from optical coherence tomography and platelet reactivity testing.
    International journal of cardiology, 2015, Apr-01, Volume: 184

    Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Coronary Res

2015
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
    Herz, 2015, Volume: 40, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr

2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, May-19, Volume: 11, Issue:1

    Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog

2015
The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study.
    Anatolian journal of cardiology, 2015, Volume: 15, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary Restenosis; Cytochrome P

2015
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel

2015
[The ISAR-SAFE study].
    Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr

2015
A case of subacute stent thrombosis after drug-coated balloon coronary angioplasty for in-stent restenosis under single anti-platelet therapy.
    Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Vessels; D

2017
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Mar-01, Volume: 89, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu

2017
Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient.
    International journal of cardiology, 2016, Sep-15, Volume: 219

    Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug-Eluting Stents; Female; HIV Infections; Hu

2016
Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
    Atherosclerosis, 2016, Volume: 251

    Topics: Adult; Aged; Alleles; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Body Ma

2016
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
    International journal of cardiology, 2017, Jun-01, Volume: 236

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal

2017
Chronic total occlusion--use of a 5 French guiding catheter in a 6 French guiding catheter.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Occlusion; Coronary Restenosis; Coronary

2008
Percutaneous treatment of a coronary aneurysm by stent graft and drug-eluting stent implantation: a potential method to reduce stent graft restenosis.
    Journal of interventional cardiology, 2008, Volume: 21, Issue:4

    Topics: Aged; Clopidogrel; Coronary Aneurysm; Coronary Restenosis; Drug-Eluting Stents; Humans; Male; Platel

2008
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma

2008
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:10

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro

2008
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Journal of the American College of Cardiology, 2008, Nov-04, Volume: 52, Issue:19

    Topics: Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Case-Control Studies; Cell Adhesion

2008
Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?
    Journal of the American College of Cardiology, 2008, Nov-04, Volume: 52, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Clopidogrel; Coronary Restenosis; Coronary

2008
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree

2009
Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
    International journal of cardiology, 2010, Sep-24, Volume: 144, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Res

2010
Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs.
    European journal of clinical investigation, 2009, Volume: 39, Issue:3

    Topics: Animals; Aspirin; Clopidogrel; Coronary Restenosis; Disease Models, Animal; Drug Therapy, Combinatio

2009
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A

2009
Bridging with GP IIb/IIIa inhibitors after abdominal surgery in a patient presenting with late stent thrombosis of a drug-eluting stent and who cannot receive oral antiplatelet treatment.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elu

2009
[Late thrombosis in paclitaxel-eluting stent after discontinuation of clopidogrel medication - a case report with 2-year follow-up].
    Kardiologia polska, 2009, Volume: 67, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiogra

2009
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:1

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosi

2008
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo

2009
[Patients with coronary artery stents: when and how should operations be carried out?].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru

2009
[Drug-eluting stents: implications for surgery patients].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6

    Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res

2009
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra

2008
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materia

2009
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco

2009
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass;

2009
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Analysis of Variance; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting S

2009
Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspirin; Coronary Angiography; Co

2009
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis

2009
Regarding comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy: problems with listing patients receiving clopidogrel for re-transplantation.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Humans; Plate

2009
Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings.
    Journal of the American College of Cardiology, 2009, Jun-02, Volume: 53, Issue:22

    Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Aneurysm; Coronary Angiography; Coronary Re

2009
Can we override clopidogrel resistance?
    Circulation, 2009, Jun-02, Volume: 119, Issue:21

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clo

2009
Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire international, 2009, Volume: 18, Issue:100

    Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co

2009
The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.
    Journal of interventional cardiology, 2009, Volume: 22, Issue:6

    Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Clopidogrel; Confidence Intervals; Co

2009
Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
    Journal of interventional cardiology, 2009, Volume: 22, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography

2009
Are we sure we have taken the best from clopidogrel?
    American heart journal, 2009, Volume: 158, Issue:4

    Topics: Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Ou

2009
Risk and benefit of proton pump inhibitor for patients undergoing anti-platelet therapy including clopidogrel.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:21

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Ther

2009
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Circulation, 2009, Dec-01, Volume: 120, Issue:22

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor

2009
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis;

2008
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor

2008
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    The Journal of invasive cardiology, 2010, Volume: 22, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi

2010
[Non-occlusive stent thrombosis associated to cardiocirculatory arrest].
    Medicina intensiva, 2010, Volume: 34, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosi

2010
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
    Journal of the American College of Cardiology, 2010, Feb-16, Volume: 55, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary

2010
Delays of event adjudication in the TRITON trial.
    Cardiology, 2010, Volume: 115, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary

2010
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:5

    Topics: Aged; Amlodipine; Angioplasty; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platel

2010
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
    MMW Fortschritte der Medizin, 2010, Mar-25, Volume: 152, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar

2010
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
    Archives of internal medicine, 2010, Apr-26, Volume: 170, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Confidence

2010
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
    American heart journal, 2010, Volume: 160, Issue:2

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary

2010
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
    Der Internist, 2010, Volume: 51, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona

2010
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    American heart journal, 2010, Volume: 160, Issue:3

    Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Car

2010
Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial I

2010
[Efficacy of stents coated with antibody against CD105 on preventing restenosis and thrombosis in minipigs].
    Zhonghua xin xue guan bing za zhi, 2010, Volume: 38, Issue:7

    Topics: Animals; Antibodies; Antigens, CD; Aspirin; Clopidogrel; Coronary Restenosis; Endothelial Cells; Neo

2010
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2

    Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro

2011
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy.
    Surgical endoscopy, 2011, Volume: 25, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Restenosis; Fem

2011
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
    Clinical cardiology, 2011, Volume: 34, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Co

2011
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kardiologia polska, 2011, Volume: 69, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati

2011
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
    Clinical cardiology, 2011, Volume: 34, Issue:9

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elut

2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
    The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb

2011
One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: insights from Spanish multicenter registry.
    Journal of interventional cardiology, 2011, Volume: 24, Issue:6

    Topics: Angioplasty, Balloon; Anticoagulants; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confi

2011
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Cardiology journal, 2011, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan

2011
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru

2012
[Effects of proton pump inhibitors on in-stent restenosis in patients receiving clopidogrel: a retrospective analysis].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2011, Volume: 40, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Antagonism; Drug Therapy, Com

2011
Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.
    Interactive cardiovascular and thoracic surgery, 2012, Volume: 14, Issue:3

    Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Restenosis; Dose

2012
eComment. Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.
    Interactive cardiovascular and thoracic surgery, 2012, Volume: 14, Issue:3

    Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Restenosis; Female; Humans; Male; Postoperat

2012
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Dec-01, Volume: 80, Issue:7

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents;

2012
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl

2012
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
    Minerva medica, 2012, Volume: 103, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration

2012
[General antithrombotic therapy practice facing fundamental change].
    MMW Fortschritte der Medizin, 2012, Sep-10, Volume: 154, Issue:15

    Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A

2012
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Corona

2012
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
    International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3

    Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor

2013
Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients.
    Platelets, 2002, Volume: 13, Issue:8

    Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Blood Platelets;

2002
Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis.
    The American journal of cardiology, 2003, Jan-15, Volume: 91, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary T

2003
The IST registry.
    Zeitschrift fur Kardiologie, 2002, Volume: 91 Suppl 3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Brachytherapy; Clopidogrel; Coronary Resten

2002
[Off-label use of clopidogrel after coronary stent implantation in Germany: optional or mandatory?].
    Herz, 2003, Volume: 28, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Approval; Drug Costs; Drug Prescr

2003
Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 59, Issue:1

    Topics: Brachytherapy; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Female; Humans; Male; Midd

2003
Brachytherapy for in-stent restenosis: the problem is one of commitment.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 59, Issue:1

    Topics: Brachytherapy; Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Recurrence

2003
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 59, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio

2003
Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 60, Issue:1

    Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Arteries; Aspirin; Blood Vessel Prosthesis Implantat

2003
Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
    The American journal of cardiology, 2003, Oct-15, Volume: 92, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary Thrombo

2003
Catheter based intracoronary brachytherapy leads to increased platelet activation.
    Heart (British Cardiac Society), 2004, Volume: 90, Issue:2

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelets; Brachythe

2004
Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues.
    Heart (British Cardiac Society), 2004, Volume: 90, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Erup

2004
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona

2004
[Interaction of statins with clopidogrel].
    Der Internist, 2004, Volume: 45, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biotransformation; Cause of Death; Clinica

2004
Paclitaxel-eluting coronary stents.
    The New England journal of medicine, 2004, May-13, Volume: 350, Issue:20

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Humans; Paclita

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance marks recurrent risks.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance;

2004
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
    The American journal of cardiology, 2004, Aug-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Case-Control Studies; Clopidogrel;

2004
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona

2004
Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Cost-Benefit Analysis; Humans; Myo

2004
[How does it work? Coronary stent implantation].
    MMW Fortschritte der Medizin, 2004, Jun-03, Volume: 146, Issue:23

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug T

2004
Severe stenosis of anastomoses by using the symmetry aortic connector system.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:5

    Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter

2004
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:2

    Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis

2005
Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Restenosis; Femal

2005
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
    The heart surgery forum, 2005, Volume: 8, Issue:1

    Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa;

2005
Very late thrombosis after implantation of sirolimus eluting stent.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar

2005
Ischemia-driven target vessel revascularization after-primary percutaneous coronary intervention: patients at risk and their outcomes.
    Journal of interventional cardiology, 2005, Volume: 18, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cineangiography; Clinical Tria

2005
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono

2005
Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?
    Scandinavian cardiovascular journal : SCJ, 2005, Volume: 39, Issue:3

    Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Coronary Stenosis; Humans; Platelet Aggreg

2005
Letter regarding article by Valgimigli et al, "Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease".
    Circulation, 2005, Nov-01, Volume: 112, Issue:18

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Implants; H

2005
[Clarification of patients at risk from the use of laminated stents].
    Deutsche medizinische Wochenschrift (1946), 2006, Jan-05, Volume: 131, Issue:1-2

    Topics: Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stents; Tic

2006
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs.
    Stroke, 2006, Volume: 37, Issue:2

    Topics: Alloys; Angioplasty, Balloon, Coronary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; A

2006
Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.
    International journal of cardiology, 2006, Apr-14, Volume: 108, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Mult

2006
[The effect of paclitaxel-eluting stents on restenosis].
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2006, Volume: 6, Issue:1

    Topics: Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di

2006
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest

2006
Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Cardiomyopathy, Dilated; Clopidogrel; Coronary Artery Bypass; Corona

2006
Clopidogrel desensitization.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:5

    Topics: Aged; Angioplasty; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Desensitization, Immun

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
    Circulation, 2006, Jun-20, Volume: 113, Issue:24

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clop

2006
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:8

    Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno

2006
Long-term clinical outcome of patients treated with beta-brachytherapy in routine clinical practice.
    International journal of cardiology, 2007, Feb-07, Volume: 115, Issue:2

    Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studi

2007
End-stage renal disease and drug-eluting stents: one small step forward.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; I

2006
Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; C

2006
Premature discontinuation of antiplatelet therapy in patients with drug-eluting coronary stents.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Dec-01, Volume: 63, Issue:23

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Vessels; Delayed-Action Preparations; Humans; Pa

2006
Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent.
    International heart journal, 2006, Volume: 47, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Fibrinolytic Agents; Foll

2006
Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery.
    British journal of anaesthesia, 2007, Volume: 98, Issue:1

    Topics: Aged; Clopidogrel; Coated Materials, Biocompatible; Coronary Restenosis; Drug Administration Schedul

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction].
    Journal of cardiology, 2006, Volume: 48, Issue:5

    Topics: Aged; Coronary Restenosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggreg

2006
Drug eluting stents.
    BMJ (Clinical research ed.), 2006, Dec-16, Volume: 333, Issue:7581

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Implants; Humans; Platelet Ag

2006
Stent thrombosis: consider also low response to antiplatelets.
    BMJ (Clinical research ed.), 2007, Jan-13, Volume: 334, Issue:7584

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr

2007
Stent thrombosis: patient card on discontinuing clopidogrel is available.
    BMJ (Clinical research ed.), 2007, Jan-13, Volume: 334, Issue:7584

    Topics: Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Medical Records; Plate

2007
Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fem

2007
Late blood clots tarnish drug-coated stents. Uncommon complication raises questions about who really needs a drug-coated stent and how long to continue drug therapy after getting one.
    Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:7

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Drug Implants; Forecasting; Foreign Bodies; Humans; Plate

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
[Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to treatment?].
    Annales pharmaceutiques francaises, 2007, Volume: 65, Issue:3

    Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Colla

2007
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2007
Clopidogrel and stent thrombosis after percutaneous coronary intervention.
    The New Zealand medical journal, 2007, Jun-01, Volume: 120, Issue:1255

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombo

2007
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Circulation, 2007, Jun-26, Volume: 115, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi

2007
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Jul-01, Volume: 64, Issue:13

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Hu

2007
[Analysis of clinical factors that influence re-stenosis after percutaneous coronary stenting].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2007, Volume: 127, Issue:8

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Restenosis; Fe

2007
Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents.
    Journal of interventional cardiology, 2007, Volume: 20, Issue:5

    Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; He

2007
Coronary artery stents and non-cardiac surgery.
    British journal of anaesthesia, 2008, Volume: 100, Issue:1

    Topics: Clopidogrel; Coronary Restenosis; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Pract

2008
Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:3

    Topics: Aged; Angiography; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Midd

2008
Restrictive access to clopidogrel and mortality following coronary stent implantation.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Feb-12, Volume: 178, Issue:4

    Topics: Aged; Canada; Cause of Death; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary

2008
Very late thrombosis in a bare metal stent: an under-recognized problem.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male;

2008
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor

2008
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cor

2008